Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa safety study of autologous mesenchymal stem cells for non-revascularizable critical limb ischemia
2012-000290-23Phase 2Completed
- Sponsor
- FIBHULP
- Start
- Nov 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous expanded mesenchymal stem cells in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans, sponsored by FIBHULP. Primary endpoint: Feasibility and safety. Started Nov 2012; status: completed.
02
Drugs
autologous expanded mesenchymal stem cells
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on 2012-000290-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000290-23.